Your browser doesn't support javascript.
loading
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
Matulonis, Ursula A; Walder, Lydia; Nøttrup, Trine J; Bessette, Paul; Mahner, Sven; Gil-Martin, Marta; Kalbacher, Elsa; Ledermann, Jonathan A; Wenham, Robert M; Woie, Kathrine; Lau, Susie; Marmé, Frederik; Casado Herraez, Antonio; Hardy-Bessard, Anne-Claire; Banerjee, Susana; Lindahl, Gabriel; Benigno, Benedict; Buscema, Joseph; Travers, Karin; Guy, Holly; Mirza, Mansoor R.
Afiliación
  • Matulonis UA; Dana-Farber Cancer Institute, Boston, MA.
  • Walder L; FIECON, Ltd, St Albans, United Kingdom.
  • Nøttrup TJ; Nordic Society of Gynaecological Oncology and Copenhagen University Hospital, Copenhagen, Denmark.
  • Bessette P; PMHC and University of Sherbrooke, Sherbrooke, Québec, Canada.
  • Mahner S; Arbeitsgemeinschaft Gynäkologische Onkologie and University of Munich, Munich, Germany.
  • Gil-Martin M; Grupo Español de Investigación en Cáncer de Ovario and Institut Català d'Oncologia-IDIBELL, L'Hospitalet, Barcelona, Spain.
  • Kalbacher E; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens and University Hospital Besançon, Besançon, France.
  • Ledermann JA; National Cancer Research Institute and University College London Cancer Institute, London, United Kingdom.
  • Wenham RM; H. Lee Moffitt Cancer Center, Tampa, FL.
  • Woie K; Nordic Society of Gynaecological Oncology and Haukeland University Hospital, Bergen, Norway.
  • Lau S; PMHC and Jewish General Hospital, Montreal, Québec, Canada.
  • Marmé F; Arbeitsgemeinschaft Gynäkologische Onkologie and Universitätsklinikum Heidelberg, Heidelberg, Germany.
  • Casado Herraez A; Grupo Español de Investigación en Cáncer de Ovario and Hospital Universitario San Carlos, Madrid, Spain.
  • Hardy-Bessard AC; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens and Centre Amoricain D'Oncologie, Paris, France.
  • Banerjee S; National Cancer Research Institute and The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom.
  • Lindahl G; Nordic Society of Gynaecological Oncology and Linköping University Hospital, Linköping, Sweden.
  • Benigno B; Northside Hospital, Atlanta, GA.
  • Buscema J; Arizona Oncology, Tucson, AZ.
  • Travers K; TESARO: A GSK Company, Waltham, MA.
  • Guy H; FIECON, Ltd, St Albans, United Kingdom.
  • Mirza MR; Nordic Society of Gynaecological Oncology and Copenhagen University Hospital, Copenhagen, Denmark.
J Clin Oncol ; 37(34): 3183-3191, 2019 12 01.
Article en En | MEDLINE | ID: mdl-31518175
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Piperidinas / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Indazoles / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Female / Humans Idioma: En Revista: J Clin Oncol Año: 2019 Tipo del documento: Article País de afiliación: Marruecos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Piperidinas / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Indazoles / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Female / Humans Idioma: En Revista: J Clin Oncol Año: 2019 Tipo del documento: Article País de afiliación: Marruecos